Liraglutide Investigated for Reducing Dietary Lipid-Induced Insulin Resistance in Humans

Insulin resistance is a key feature of Type 2 Diabetes and often exacerbated by diets high in saturated fats. This metabolic dysfunction impairs glucose uptake and contributes to disease progression. Current therapies primarily target glucose control but may not directly address the underlying lipid-induced insulin resistance. Liraglutide, a GLP-1 receptor agonist, is known for its glucose-lowering effects and potential metabolic benefits beyond glycemic control, making it a candidate for mitigating dietary lipid-induced metabolic dysfunction.

This Phase 1 clinical trial enrolled 20 human participants with Type 2 Diabetes to investigate the effects of Liraglutide on insulin resistance. The study aimed to assess whether Liraglutide could reduce insulin resistance that develops from eating a diet high in saturated fats. Specific details regarding dosage, administration route, frequency, duration, primary endpoints, and control arm are not provided in the available research record.

The provided research record, which describes the study's objective, does not include any specific findings, numerical results, or statistical data from the completed trial. While the study is listed as 'COMPLETED' with an actual enrollment of 20 participants, the abstract focuses solely on the investigative aim: to test the effects of Liraglutide on dietary lipid-induced insulin resistance in humans. Consequently, no percentages, p-values, fold-changes, or specific pathway modulations can be reported from this source.